{"id":"nemonoxacin","rwe":[],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"J01MB08","category":"atc"},{"label":"Active","category":"status"},{"label":"Community acquired pneumonia","category":"indication"},{"label":"Anti-Bacterial Agents","category":"pharmacology"},{"label":"Anti-Infective Agents","category":"pharmacology"}],"phase":"phase_3","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"taigexyn","offLabel":[],"synonyms":["nemonoxacin","taigexyn","TG 873870","TG-873870"],"timeline":[],"aiSummary":"Taigexyn, also known as Nemonoxacin, is a small molecule that inhibits bacterial DNA gyrase, a mechanism that targets bacterial DNA replication. It has been studied for its safety and efficacy in treating Diabetic Foot Infections and Pneumonia, with doses of 500 mg and 650 mg being investigated.","approvals":[],"brandName":"Taigexyn","ecosystem":[{"indication":"Community acquired pneumonia","otherDrugs":[{"name":"ertapenem","slug":"ertapenem","company":"Merck Sharp Dohme"}],"globalPrevalence":null}],"mechanism":{"modality":"Small Molecule","explanation":"Think of it like a copy machine. Bacteria make copies of their DNA to multiply. Taigexyn blocks this process, preventing the bacteria from making more copies and eventually killing them.","oneSentence":"Taigexyn works by inhibiting bacterial DNA replication and transcription.","technicalDetail":"Taigexyn is a quinolone antibiotic that targets bacterial DNA gyrase and topoisomerase IV, enzymes essential for bacterial DNA replication and transcription."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5079","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=NEMONOXACIN","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=NEMONOXACIN","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T12:55:41.742280","biosimilars":[],"competitors":[{"drugName":"nalidixic acid","drugSlug":"nalidixic-acid","fdaApproval":"1964-03-06","genericCount":2,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"cinoxacin","drugSlug":"cinoxacin","fdaApproval":"1980-06-13","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"genericName":"nemonoxacin","indications":{"approved":[{"name":"Community acquired pneumonia","source":"DrugCentral","snomedId":385093006,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"nalidixic-acid","brandName":"nalidixic acid","genericName":"nalidixic acid","approvalYear":"1964","relationship":"same-class"},{"drugId":"cinoxacin","brandName":"cinoxacin","genericName":"cinoxacin","approvalYear":"1980","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT00685698","phase":"PHASE2","title":"Safety and Efficacy Study of TG-873870 (Nemonoxacin) in Diabetic Foot Infections","status":"COMPLETED","sponsor":"TaiGen Biotechnology Co., Ltd.","startDate":"2008-06","conditions":["Diabetic Foot Infections"],"enrollment":40,"completionDate":"2009-06"},{"nctId":"NCT01944774","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of Intravenous Infusion With Nemonoxacin Malate Sodium Chloride","status":"COMPLETED","sponsor":"TaiGen Biotechnology Co., Ltd.","startDate":"2013-03","conditions":["Pneumonia"],"enrollment":207,"completionDate":"2013-12"},{"nctId":"NCT06959667","phase":"","title":"Comparative Analysis of Nemonoxacin and Other Anti-methicillin Resistant Staphylococcus Aureus (Anti-MRSA) Antimicrobial Therapy in Patients With Complicated Skin and Soft Tissue Infections (cSSTI): a Retrospective Chart Review Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2025-04-15","conditions":["Methicillin-susceptible S. Aureus (MSSA)","Anti-methicillin Resistant Staphylococcus Aureus (Anti-MRSA)","Complicated Skin and Soft Tissue,cSSTI"],"enrollment":144,"completionDate":"2025-12-31"},{"nctId":"NCT03551210","phase":"PHASE3","title":"Efficacy and Safety of Nemonoxacin vs Levofloxacin in Adult Patients With Community-Acquired Pneumonia","status":"COMPLETED","sponsor":"R-Pharm","startDate":"2016-05-04","conditions":["Pneumonia, Bacterial"],"enrollment":342,"completionDate":"2017-12-26"},{"nctId":"NCT05133752","phase":"PHASE4","title":"Oral Nemonoxacin in Treating Elderly Patients With CAP","status":"COMPLETED","sponsor":"TaiGen Biotechnology Co., Ltd.","startDate":"2018-09-11","conditions":["Community-acquired Pneumonia"],"enrollment":100,"completionDate":"2020-03-23"},{"nctId":"NCT02205112","phase":"PHASE3","title":"A Phase III Study to Evaluate the Efficacy and Safety of Intravenous Infusion of Nemonoxacin in Treating CAP","status":"COMPLETED","sponsor":"TaiGen Biotechnology Co., Ltd.","startDate":"2014-06","conditions":["Community-acquired Pneumonia"],"enrollment":598,"completionDate":"2017-05-15"},{"nctId":"NCT02840812","phase":"PHASE1","title":"Pharmacokinetics Study of Nemonoxacin Malate Capsules in Subjects With Severe Impaired Renal Function","status":"UNKNOWN","sponsor":"Zhejiang Medicine Co., Ltd.","startDate":"2017-04-05","conditions":["Kidney Dysfunction"],"enrollment":24,"completionDate":"2019-01"},{"nctId":"NCT02604498","phase":"PHASE1","title":"Pharmacokinetics Study of Nemonoxacin Malate Capsules in Subjects With Moderate Impaired Hepatic Function","status":"COMPLETED","sponsor":"Zhejiang Medicine Co., Ltd.","startDate":"2016-04-14","conditions":["Liver Dysfunction"],"enrollment":20,"completionDate":"2018-01-15"},{"nctId":"NCT01537250","phase":"PHASE2","title":"Phase II Clinical Study to Assess the Efficacy and Safety of Nemonoxacin Malate in Treating Adult Patients With Community-acquired Pneumonia (CAP)","status":"COMPLETED","sponsor":"TaiGen Biotechnology Co., Ltd.","startDate":"2009-08","conditions":["Community-acquired Pneumonia"],"enrollment":192,"completionDate":"2010-08"},{"nctId":"NCT03362853","phase":"PHASE1","title":"A Study Evaluating the Effect of a Single-dose Oral Administration of Nemonoxacin Capsule on QTc Intervals and Heart Rhythms of Healthy Subjects and the Influence of Food Intake on QTc Intervals and Pharmacokinetic Characteristics","status":"COMPLETED","sponsor":"TaiGen Biotechnology Co., Ltd.","startDate":"2012-06-25","conditions":["Healthy Volunteers"],"enrollment":48,"completionDate":"2012-08-10"},{"nctId":"NCT01529476","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Oral Administration With Nemonoxacin and Levofloxacin in Patients With CAP","status":"COMPLETED","sponsor":"TaiGen Biotechnology Co., Ltd.","startDate":"2011-04","conditions":["Pneumonia"],"enrollment":540,"completionDate":"2012-12"},{"nctId":"NCT01529957","phase":"PHASE1","title":"A Study of Nemonoxacin Malate Sodium Chloride Injection Administered by Intravenous Infusion","status":"COMPLETED","sponsor":"TaiGen Biotechnology Co., Ltd.","startDate":"2008-09","conditions":["Healthy"],"enrollment":176,"completionDate":"2011-03"},{"nctId":"NCT01395108","phase":"PHASE1","title":"Clinical Study on Oral Nemonoxacin Malate Capsules","status":"COMPLETED","sponsor":"TaiGen Biotechnology Co., Ltd.","startDate":"2008-01","conditions":["Healthy Volunteers"],"enrollment":76,"completionDate":"2008-08"},{"nctId":"NCT00434291","phase":"PHASE2","title":"Safety and Efficacy Comparison of TG-873870(Nemonoxacin) to Levofloxacin in Community-Acquired Pneumonia","status":"COMPLETED","sponsor":"TaiGen Biotechnology Co., Ltd.","startDate":"2006-12","conditions":["Community-Acquired Pneumonia"],"enrollment":264,"completionDate":"2007-08"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"P94L0PVO94","CHEBI":"CHEBI:136053","INN_ID":"8789","UMLSCUI":"C2742587","ChEMBL_ID":"CHEMBL1213456","DRUGBANK_ID":"DB06600","PUBCHEM_CID":"11993740","IUPHAR_LIGAND_ID":"10836","MESH_SUPPLEMENTAL_RECORD_UI":"C543520"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","halfLife":"13.5 hours","clearance":"3.8 mL/min/kg","fractionUnbound":"0.84%","volumeOfDistribution":"1.9 L/kg"},"publicationCount":90,"therapeuticAreas":["Infectious Disease"],"atcClassification":{"source":"DrugCentral","atcCode":"J01MB08","allCodes":["J01MB08"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}